SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)
Amendment No. 4
COMMUNITY MEDICAL TRANSPORT, INC.
- ----------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.001 par value
- -----------------------------------------------------------------------------
(Title of Class of Securities)
203744107
- -----------------------------------------------------------------------------
(CUSIP Number)
Mr. Craig V. Sloane
Community Medical Transport, Inc.
4 Gannett Drive
White Plain, New York 10604
(914) 697-9233
- -----------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
March 24, 2000
- -----------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check
the following box [ ].
Note: Schedules filed in paper format shall include a signed original
and five copies of the schedule, including all exhibits. See Rule 13d-7 for
other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of
that section of the Exchange Act but shall be subject to all other provisions
of the Exchange Act.
CUSIP NO. 203744107 13D Page 2 of 5 pages
___________________________________________________________________________
1 NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Herbard Limited (no. Fed. I.D. No.)
___________________________________________________________________________
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [ ]
___________________________________________________________________________
3 SEC USE ONLY
___________________________________________________________________________
4 SOURCE OF FUNDS*
WC
___________________________________________________________________________
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(d) or 2(e) [ ]
___________________________________________________________________________
6 CITIZENSHIP OR PLACE OF ORGANIZATION
British Virgin Islands
___________________________________________________________________________
7 SOLE VOTING POWER
NUMBER OF 40,227 Shares
SHARES
___________________________________________________________________________
8 SHARED VOTING POWER
BENEFICIALLY
0
OWNED BY
___________________________________________________________________________
EACH 9 SOLE DISPOSITIVE POWER
REPORTING 40,227 Shares
___________________________________________________________________________
PERSON 10 SHARED DISPOSITIVE POWER
WITH 0
___________________________________________________________________________
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON
40,227 Shares
___________________________________________________________________________
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* [ ]
___________________________________________________________________________
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
3.96%
___________________________________________________________________________
14 TYPE OF REPORTING PERSON
CO
___________________________________________________________________________
<PAGE>
CUSIP NO. 203744107 13D Page 3 of 5 Pages
Item 1 Security and Issuer
This statement on Schedule 13D (the "Amendment"), filed with
respect to events that occurred on March 24, 2000, relates to shares of
Common Stock, par value $0.001 per share, of Community Medical Transport,
Inc., a Delaware corporation (the"Common Stock" and the "Issuer",
respectively), whose principal executive offices are located at 4 Gannett
Drive, White Plains, New York, 10604.
Item 2 Identity and Backround
This Statement is filed by Herbard Limited, a British Virgin
Islands corporation ("Herbard").
Herbard may be deemed to be controlled by the Phyllis Quasha
Revocable Trust. Phyllis G. Quasha, as the settlor of the Trust, may be
deemed to control the Trust. Based upon the foregoing considerations, for
purposes of General Instruction C to Schedule 13D, the Phyllis Quasha
Revocable Trust and Phyllis G. Quasha (collectively, the "Instruction C
Persons") may be deemed to control Herbard.
Exhibit A, previously filed as Exhibit A to the Schedule 13D filed
with the Securities and Exchange Commission on October 8, 1998, sets forth
the name, place of organization, principal business, address of principal
business and address of principal office of Herbard and each Instruction C
Person.
The name, citizenship, business address and present principal
occupation or employment of each executive officer and director of Herbard
and each of the Instruction C Persons, as well as the name, principal
business and address of the corporation or other organization in which such
occupation or employment is conducted, are set forth in Exhibit B to the
Schedule 13D filed with the Securities and Exchange Commission on October 8,
1998.
During the five years prior to the date hereof, neither Herbard
nor, to the best of their knowledge, any of the Instruction C Persons or any
executive officer or director of Herbard or any of the Instruction C Persons,
(i) have been convicted in a criminal proceeding (excluding traffic
violations or similar misdemeanors) or (ii) has been a party to a civil
proceeding of a judicial or administrative body of competent jurisdiction,
as a result of which such person was or is subject to a judgment, decree or
final order enjoining future violations of, or prohibiting or mandating
activities subject to, federal or state securities laws or finding any
violation with respect to such laws.
Item 3 Source and Amount of Funds or Other Consideration
Since the filing of Amendment No. 3 to Schedule 13-D on January 12,
1999, Herbard purchased 10,176 shares of Common Stock for an aggregate
purchase price of $20,988 which was paid with Herbard's general corporate
funds.
CUSIP NO. 203744107 13D Page 4 of 5 Pages
Item 4 Purpose of the Transaction
The acquisition and disposition of the Common Stock of the Issuer,
reported herein, has been a part of the general investment activities of
Herbard without any intent to influence or control the Issuer.
Item 5 Interest in Securities of the Issuer
(a) & (b) As of September 30, 1999, the Issuer had a total of
1,015,947 shares of Common Stock issued and outstanding according to its Form
10Q SB/A filed on November 22, 1999 for the quarter ending September 30,
1999.
Pursuant to Rule 13d-3, the Reporting Person may be deemed to
beneficially own an aggregate of 40,227 Shares. Pursuant to Rule 13d-3 (d)
(1) (i), such 40,227 Shares constitute an aggregate of approximately 3.96% of
the outstanding Common Stock.
(c) During the past 60 days, Herbard has made the following sales
in the over-the-counter market: (i) on March 24, 2000, 50,000 shares of
Common Stock were sold at $4.1688 per share; (ii) on March 27, 2000, 25,000
shares of Common Stock were sold at $4.125 per share; and (iii) on March 29,
2000, 5,000 shares of Common Stock were sold at $4.125 per share. Such sales
transactions have reduced the number of shares of Common Stock Herbard holds
to 40,227.
(d) Inapplicable
(e) On March 24, 2000, Herbard ceased being the beneficial owner
of more than 5% of the Common Stock of the Issuer.
Item 6 Contracts, Arrangements, Understandings or Relationships with
respect to Securities of the Issuer.
Neither Herbard nor, to the best of its knowledge, any executive
officer or director thereof, has any contract, arrangement, understanding or
relationship with one or more security holders of the Issuer or others, with
respect to the purchase, holding, voting or disposition of shares of Common
Stock or other securities of the Issuer which are convertible or exercisable
into such shares. Each of such persons reserves the right to enter into any
such contract, arrangement, understanding or relationship in the future.
Item 7 Material to be Filed as Exhibits
None.
<PAGE>
CUSIP NO. 203744107 13D Page 5 of 5 Pages
SIGNATURES
After reasonable inquiry and to the best of its knowledge and
belief, the undersigned certifies that the information set forth in this
statement is true, complete and correct.
Dated: April 4, 2000.
HERBARD LIMITED
By: /s/ Thomas A. Huser
---------------------
Thomas A. Huser
Attorney-in-Fact
